Genea offers IVF patients the best chance of success

Genea patients are more likely to have a baby according to a comparison of our success rates with the average of other clinics based on new data published today.

The report from the Australian Institute of Health and Welfare details approximately 61,800 cycles of assisted reproductive technology (ART) treatments carried out in Australia and New Zealand in 2010.

It reveals that overall 24 per cent of treatment cycles resulted in a pregnancy and 18 per cent in a live birth.

However, at Genea clinics, 30 per cent of cycles resulted in a pregnancy and 23 per cent in a live birth – meaning our patients had more than a 30 per cent greater chance of taking home a baby.

In other words, for every 100 patients who began a treatment cycle at a Genea clinic, 23 babies were born. But for every 100 patients who had IVF cycles at other clinics, only 17 live births occurred, according to a comparison of Genea success rates to results from all other clinics.

If the chance of success for Genea patients was extrapolated to all of the cycles carried out at all clinics during 2010, you could expect that approximately 3,500 babies more would have been born.

“We are extremely proud that this national data has confirmed once again that we are able to offer patients the best chance of taking home a healthy baby through our world leading science and patient care,” Genea CEO Dr Kylie deBoer said.

The AIHW report has also confirmed previous studies which found there was a decrease in the number of IVF cycles undertaken in 2010 compared to previous years – which coincided with a reduction in the Medicare rebate for patients.

However, Genea Medical Director Associate Professor Mark Bowman said that after an initial decline during 2010, cycle numbers have rebounded to the levels prior to the Medicare rebate changes.

“Our own analysis shows that of Genea patients who have a baby, nine out of ten will do so within three or less cycles of IVF. We are also seeing more and more patients completing their family from just one stimulated cycle of IVF*, due to the great improvements we have seen in births from frozen embryo transfers,” Assoc Prof Bowman said.

During IVF, embryos are created by combining eggs and sperm in the lab. At Genea, they develop in the laboratory for five or six days. The best quality embryo will usually be selected for a fresh transfer, but many couples also have embryos that can be frozen and stored for later use.

A slight overall increase in the pregnancy rates from frozen embryos was revealed by the AIHW report when looking at the data for all clinics.

But, at Genea success from frozen embryo transfers are significantly higher. The pregnancy rate per frozen embryo transfer in women of all ages was 27 per cent nationally, but more than 35 per cent at Genea.

Success rates are particularly impressive for older women – with 31 per cent of frozen embryo transfers in Genea patients aged more than 38 resulting in a pregnancy – compared to an average of 21 per cent at other clinics.

That represents a more than 50 per cent greater chance of our older patients becoming pregnant from a frozen embryo transfer.

The results have led Genea to introduce clinical a trial whereby some patients will have all embryos frozen following a stimulation cycle. The aim is to determine if pregnancy and live birth rates can be improved still further by only using frozen embryos transferred during a woman’s natural cycle, rather than following hormone stimulation that is required during an IVF cycle.

“We are very focused on minimising the number of times a woman needs to have ovarian stimulation - to develop eggs and then embryos,” Assoc Prof Bowman said.

The increased success from frozen embryo transfers also reinforces the Genea approach of transferring one embryo at a time – minimising the risks associated with multiple births.

Genea Scientific Director Steven McArthur, said the improved outcomes from the transfer of frozen embryos and the introduction of the trial were a reflection of Genea’s continued focus on improvements in all areas of the science of IVF.

“We continue to lead the way in the development and implementation of world leading science to the benefit of patients seeking a pregnancy from IVF.”

* Based on patients who had their first cycle of IVF between January 1st 2010 and December 31st 2010, resulting in an embryo transfer, who were followed through their IVF journey.

More on Genea's success rates
About Assoc Prof Mark Bowman
Meline Walton
Media & Communications Manager
M +61 452 433 369